SGI-1776

· Astex Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for SGI-1776, covering 2024-08-02 to 2024-08-02. Get the full timeline:

Most recent: Clinical Trial Update: Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma [Phase 1]

See pricing